Oruka Therapeutics (ORKA) Retained Earnings (2010 - 2026)

Oruka Therapeutics' Retained Earnings history runs 17 years deep, the most recent figure standing at -$480000.0 for Q1 2026.

• On a quarterly basis, Retained Earnings fell 100.1% year-over-year to -$480000.0 in Q1 2026; TTM through Mar 2026 was -$480000.0, a 100.1% decrease from a year earlier, with the FY2025 full-year figure at $657.6 million, up 885.39% from the prior year.
• Retained Earnings declined to -$480000.0 in Q1 2026 per ORKA's latest filing, from $657.6 million in the prior quarter.
• Across five years, Retained Earnings topped out at $657.6 million in Q4 2025 and bottomed at -$193.4 million in Q2 2024.
• The 5-year median for Retained Earnings is -$179.9 million (2022), against an average of -$23.6 million.
• Across the five-year window, Retained Earnings surged 885.39% in 2025 and plunged 100.1% in 2026, its largest moves.
• Year by year, Retained Earnings stood at -$183.4 million in 2022, then retreated by 2.91% to -$188.7 million in 2023, then soared by 55.64% to -$83.7 million in 2024, then jumped by 885.39% to $657.6 million in 2025, then slumped by 100.07% to -$480000.0 in 2026.
• Per Business Quant, the three latest ORKA Retained Earnings figures stand at -$480000.0 (Q1 2026), $657.6 million (Q4 2025), and $185000.0 (Q3 2025).